Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 27, 2007

Ipsen Grants Technology to and Takes Stake in PregLem

  • PregLem signed a licensing agreement with Ipsen under which Ipsen will grant PregLem worldwide development and commercialization rights to certain Ipsen compounds, for use in reproductive medicine only.

    Sutrepa (an affiliate of Ipsen) has taken a minority equity stake in PregLem and will appoint a representative to its board of directors. PregLem is a biopharmaceutical company specialized in reproductive medicine. It is focused on the development and commercialization of innovative compounds for the treatment of benign gynecological conditions and infertility.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »